Rui M. V. Abreu

Dr. Rui M. V. Abreu

Centro de Investigação de Montanha (CIMO), Instituto Politécnico de Bragança, C.P. 5300-253 Bragança, Portugal
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Isabel FerreiraIsabel Ferreira
Isabel Ferreira
Lillian BarrosLillian Barros
Lillian Barros
Rui M. V. AbreuRui M. V. Abreu
Rui M. V. Abreu
Maintenance of equilibrium between free radical production and antioxidant defences (enzymatic and non enzymatic) is an essential condition for normal organism functioning. When this equilibrium has a tendency for the production of free radicals we say that the organism is in oxidative stress. In this situation, excess free radicals may damage cellular lipids, proteins and DNA, affecting normal function and leading to various diseases. In aerobic organisms, the free radicals are constantly produced during the normal cellular metabolism, mainly in the form of Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS). Exposition of the organism to free radicals has led to the development of endogenous defence mechanisms to eliminate them. These defences were the response of evolution to the inevitability of ROS production in aerobic conditions. Natural products with antioxidant activity may help the endogenous defence system. In this perspective the antioxidants present in the diet assume a major importance as possible protector agents reducing oxidative damage. Particularly, the antioxidant properties of wild mushrooms have been extensively studied by our research group and by others, and many antioxidant compounds extracted from these sources have been identified, such as phenolic compounds, tocopherols, ascorbic acid, and carotenoids. We will review the compounds identified so far in mushrooms, as well as the mechanism of action involved in their antioxidant properties. Wild mushrooms might be used directly in diet and promote health, taking advantage of the additive and synergistic effects of all the bioactive compounds present.

19 March 2013 in Journal of Applied Microbiology
Verified
Journal Article
Open access
PDF file
MAM.J. Alves
M.J. Alves
Isabel FerreiraIsabel Ferreira
Isabel Ferreira
HFH.J.C. Froufe
H.J.C. Froufe
Rui M. V. AbreuRui M. V. Abreu
Rui M. V. Abreu
AMAnabela Lourenço Martins Martins
Anabela Lourenço Martins Martins
Manuela PintadoManuela Pintado
Manuela Pintado
Aim and Methods Although the antimicrobial activity of extracts from several mushroom species has been reported, studies with the individual compounds present in that extracts are scarce. Herein, the antimicrobial activity of different phenolic compounds identified and quantified in mushroom species from all over the world was evaluated. Furthermore, a structure–activity relationship (SAR) analysis and molecular docking studies were performed, in order to provide insights into the mechanism of action of potential antimicrobial drugs for resistant micro-organisms. Results 2,4-Dihydroxybenzoic and protocatechuic acids were the phenolic compounds with higher activity against the majority of Gram-negative and Gram-positive bacteria. Furthermore, phenolic compounds inhibited more MRSA than methicillin-susceptible Staphylococcus aureus. MRSA was inhibited by 2,4-dihydroxybenzoic, vanillic, syringic (MICs = 0·5 mg ml−1) and p-coumaric (MIC = 1 mg ml−1) acids, while these compounds at the same concentrations had no inhibitory effects against methicillin-susceptible Staph. aureus. Conclusions The presence of carboxylic acid (COOH), two hydroxyl (OH) groups in para and ortho positions of the benzene ring and also a methoxyl (OCH3) group in the meta position seems to be important for anti-MRSA activity. Significance and Impact of the Study Phenolic compounds could be used as antimicrobial agents, namely against some micro-organisms resistant to commercial antibiotics.

1 February 2019 in Industrial Crops and Products
Verified
Journal Article
Closed access
LLLara Lockowandt
Lara Lockowandt
José PinelaJosé Pinela
José Pinela
CRCustódio Lobo Roriz
Custódio Lobo Roriz
Carla PereiraCarla Pereira
Carla Pereira
Rui M. V. AbreuRui M. V. Abreu
Rui M. V. Abreu
Isabel FerreiraIsabel Ferreira
Isabel Ferreira


1 October 2015 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Open access
VMVera Machado
Vera Machado
DPDaniela Peixoto
Daniela Peixoto
Raquel CostaRaquel Costa
Raquel Costa
HFHugo J.C. Froufe
Hugo J.C. Froufe
Ricardo CalhelhaRicardo Calhelha
Ricardo Calhelha
MQMaria-João Queiroz
Maria-João Queiroz
The synthesis and biological evaluation of novel 1-aryl-3-[2-, 3- or 4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 3, 4 and 5 as VEGFR-2 tyrosine kinase inhibitors, are reported. The 1-aryl-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 4a-4h, with the arylurea in the meta position to the thioether, showed the lowest IC₅₀ values in enzymatic assays (10-206 nM), the most potent compounds 4d-4h (IC₅₀ 10-28 nM) bearing hydrophobic groups (Me, F, CF₃ and Cl) in the terminal phenyl ring. A convincing rationalization was achieved for the highest potent compounds 4 as type II VEGFR-2 inhibitors, based on the simultaneous presence of: (1) the thioether linker and (2) the arylurea moiety in the meta position. For compounds 4, significant inhibition of Human Umbilical Vein Endothelial Cells (HUVECs) proliferation (BrdU assay), migration (wound-healing assay) and tube formation were observed at low concentrations. These compounds have also shown to increase apoptosis using the TUNEL assay. Immunostaining for total and phosphorylated (active) VEGFR-2 was performed by Western blotting. The phosphorylation of the receptor was significantly inhibited at 1.0 and 2.5 μM for the most promising compounds. Altogether, these findings point to an antiangiogenic effect in HUVECs.